Compare GLP & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GLP | ORKA |
|---|---|---|
| Founded | 2005 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2005 | N/A |
| Metric | GLP | ORKA |
|---|---|---|
| Price | $42.33 | $28.15 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $45.00 | ★ $48.20 |
| AVG Volume (30 Days) | 52.4K | ★ 684.0K |
| Earning Date | 11-07-2025 | 11-12-2025 |
| Dividend Yield | ★ 7.22% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.08 | N/A |
| Revenue | ★ $18,099,776,000.00 | N/A |
| Revenue This Year | $22.70 | N/A |
| Revenue Next Year | $42.12 | N/A |
| P/E Ratio | $20.11 | ★ N/A |
| Revenue Growth | ★ 4.10 | N/A |
| 52 Week Low | $39.70 | $5.49 |
| 52 Week High | $60.00 | $32.64 |
| Indicator | GLP | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 43.37 | 42.77 |
| Support Level | $41.53 | $28.15 |
| Resistance Level | $43.00 | $32.64 |
| Average True Range (ATR) | 1.22 | 2.15 |
| MACD | -0.08 | -0.34 |
| Stochastic Oscillator | 23.54 | 7.42 |
Global Partners LP is a limited partnership that acts as a midstream logistics and marketing company. It is mainly engaged in purchasing, selling, storing and logistics of transporting petroleum and related products. The company owns and operates and control terminal networks of refined petroleum products and renewable fuels in Massachusetts, Maine, Connecticut, Vermont, and other places. It distributes gasoline and gasoline blendstocks, distillates, residual oil, renewable fuels, crude oil, natural gas and propane to wholesalers, retailers and commercial customers. The company operates through three segments i.e. Wholesale, Gasoline Distribution and Station Operations and Commercial. It generates maximum revenue from the Wholesale segment.
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.